Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
Rapport Therapeutics (Nasdaq: RAPP) has announced two encore poster presentations at the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego from April 5-9, 2025. The presentations will focus on RAP-219, their clinical-stage AMPA receptor negative allosteric modulator in Phase 2 development for refractory focal epilepsy.
The first poster (#002) will present ROC analysis data showing that a 30% reduction in long episode frequency predicts a clinically meaningful reduction (≥50%) in clinical seizures. The second poster (#003) will demonstrate RAP-219's potent antiseizure effects in preclinical models, with maximal protection achieved at 70% receptor occupancy and 7 ng/mL mean plasma concentration.
Rapport Therapeutics (Nasdaq: RAPP) ha annunciato due presentazioni di poster durante il Meeting Annuale 2025 dell'Accademia Americana di Neurologia (AAN) che si terrà a San Diego dal 5 al 9 aprile 2025. Le presentazioni si concentreranno su RAP-219, il loro modulatore allosterico negativo del recettore AMPA in fase di sviluppo clinico per l'epilessia focale refrattaria.
Il primo poster (#002) presenterà dati di analisi ROC che mostrano come una riduzione del 30% nella frequenza di episodi prolungati predice una riduzione clinicamente significativa (≥50%) nelle crisi cliniche. Il secondo poster (#003) dimostrerà gli effetti potenti di RAP-219 contro le crisi in modelli preclinici, con una protezione massima raggiunta al 70% di occupazione del recettore e una concentrazione plasmatica media di 7 ng/mL.
Rapport Therapeutics (Nasdaq: RAPP) ha anunciado dos presentaciones de póster en el Congreso Anual 2025 de la Academia Americana de Neurología (AAN) que se llevará a cabo en San Diego del 5 al 9 de abril de 2025. Las presentaciones se centrarán en RAP-219, su modulador alostérico negativo del receptor AMPA en desarrollo clínico para la epilepsia focal refractaria.
El primer póster (#002) presentará datos de análisis ROC que muestran que una reducción del 30% en la frecuencia de episodios largos predice una reducción clínicamente significativa (≥50%) en las convulsiones clínicas. El segundo póster (#003) demostrará los potentes efectos anticonvulsivos de RAP-219 en modelos preclínicos, con una protección máxima alcanzada con una ocupación del receptor del 70% y una concentración plasmática media de 7 ng/mL.
Rapport Therapeutics (Nasdaq: RAPP)는 2025년 4월 5일부터 9일까지 샌디에이고에서 개최되는 2025 미국 신경학회(AAN) 연례 회의에서 두 개의 포스터 발표를 진행한다고 발표했습니다. 발표는 RAP-219, 즉 난치성 초점 간질에 대한 임상 단계의 AMPA 수용체 음성 알로스테릭 조절제에 초점을 맞출 것입니다.
첫 번째 포스터(#002)는 장기 에피소드 빈도에서 30% 감소가 임상 발작에서 임상적으로 의미 있는 감소(≥50%)를 예측한다는 ROC 분석 데이터를 제시합니다. 두 번째 포스터(#003)는 70% 수용체 점유율과 7 ng/mL 평균 혈장 농도에서 최대 보호 효과를 달성하는 RAP-219의 강력한 항발작 효과를 전시할 것입니다.
Rapport Therapeutics (Nasdaq: RAPP) a annoncé deux présentations de posters lors de la Réunion Annuelle 2025 de l'Académie Américaine de Neurologie (AAN), qui se tiendra à San Diego du 5 au 9 avril 2025. Les présentations porteront sur RAP-219, leur modulateur allostérique négatif des récepteurs AMPA en phase de développement clinique pour l'épilepsie focale réfractaire.
Le premier poster (#002) présentera des données d'analyse ROC montrant qu'une réduction de 30% de la fréquence des épisodes longs prédit une réduction cliniquement significative (≥50%) des crises cliniques. Le deuxième poster (#003) démontrera les puissants effets anti-crise de RAP-219 dans des modèles précliniques, avec une protection maximale atteinte à 70% d'occupation des récepteurs et une concentration plasmatique moyenne de 7 ng/mL.
Rapport Therapeutics (Nasdaq: RAPP) hat zwei weitere Posterpräsentationen auf dem Jahrestreffen 2025 der American Academy of Neurology (AAN) angekündigt, das vom 5. bis 9. April 2025 in San Diego stattfindet. Die Präsentationen konzentrieren sich auf RAP-219, ihren klinischen AMPA-Rezeptor-negativen allosterischen Modulator, der sich in der Phase-2-Entwicklung für refraktäre fokale Epilepsie befindet.
Das erste Poster (#002) wird ROC-Analysetdaten präsentieren, die zeigen, dass eine 30%ige Reduktion der Frequenz langer Episoden eine klinisch signifikante Reduktion (≥50%) der klinischen Anfälle vorhersagt. Das zweite Poster (#003) wird die starken antiseizurischen Effekte von RAP-219 in präklinischen Modellen demonstrieren, wobei der maximale Schutz bei 70% Rezeptorbesetzung und einer mittleren Plasmakonzentration von 7 ng/mL erreicht wird.
- None.
- None.
BOSTON and SAN DIEGO, March 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced two encore poster presentations at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, California. The data from these posters was originally presented at the American Epilepsy Society (AES) Annual Meeting in December 2024.
The presentations will highlight the company’s ongoing research and development of RAP-219, a clinical-stage AMPA receptor (AMPAR) negative allosteric modulator (NAM) currently in Phase 2 development for the treatment of refractory focal epilepsy.
Rapport will showcase the following posters:
- Poster #002: Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency (Monday, April 7, 2025 from 8:00 AM to 9:00 AM PT) –Using a receiver operator characteristic (ROC) analysis, the data confirmed that a
30% reduction in LE frequency was the optimal cut point associated with a clinically meaningful (≥50% ) reduction in clinical seizures, regardless of the antiseizure medication initiated, revealing a linear relationship between long episode and clinical seizure frequencies. - Poster #003: Antiseizure Effects with Selective TARPγ8 Negative Allosteric Modulators in Preclinical Seizure Models (Tuesday, April 8, 2025 from 11:45 AM to 12:45 PM PT) - RAP-219 provided potent, dose-dependent antiseizure effects in pentylenetretrazol (PTZ) and corneal kindling preclinical seizure models, with maximal protection observed with
70% receptor occupancy and RAP-219 mean plasma concentration of 7 ng/mL.
For more information on the AAN 2025 Annual Meeting, please visit the conference website.
About RAP-219
RAP-219 is a clinical-stage AMPA receptor (AMPAR) negative allosteric modulator (NAM) designed to achieve neuroanatomical specificity through its selective targeting of a receptor associated protein (RAP) known as TARPγ8, which is associated with neuronal AMPARs. Whereas AMPARs are distributed widely in the central nervous system, TARPγ8 is expressed only in discrete regions, including the hippocampus and neocortex, where focal seizures often originate. By contrast, TARPγ8 has minimal expression in the hindbrain, where drug effects are often associated with intolerable adverse events. With this precision approach, the Company believes RAP-219 has the potential to provide a differentiated profile as compared to traditional neuroscience medications. Due to the role of AMPA biology in various neurological disorders and the selective targeting of TARPγ8, the Company believes RAP-219 has pipeline-in-a-product potential and is evaluating the compound as a transformational treatment for patients with focal epilepsy, bipolar disorder, and peripheral neuropathic pain.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the expected impact of reductions in long episode frequency as measured by the RNS® System, including but not limited to Rapport’s ability to predict clinically meaningful seizure reduction; the clinical development of RAP-219 for the treatment of drug-resistant focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain; the potential activity and tolerability of RAP-219; and the potential of Rapport’s RAP technology platform.
Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Rapport’s business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the company’s research and development activities; Rapport’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Rapport’s ability to attract, integrate and retain key personnel; risks related to the company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Rapport’s intellectual property protections; and risks related to the competitive landscape for Rapport’s product candidates; as well as other risks described in “Risk Factors,” in the company’s Registration Statement on Form S-1, and most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Rapport’s subsequent filings with the Securities and Exchange Commission. Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Contact Julie DiCarlo Head of Communications & IR Rapport Therapeutics jdicarlo@rapportrx.com
FAQ
What are the key findings from Rapport Therapeutics' RAP-219 epilepsy drug research being presented at AAN 2025?
When and where will Rapport Therapeutics (RAPP) present their epilepsy treatment data in 2025?
What stage of development is Rapport Therapeutics' RAP-219 epilepsy treatment in?
How effective is RAP-219 in preclinical seizure models according to Rapport's research?
What is the significance of the 30% reduction in long episode frequency shown in Rapport's epilepsy research?
